In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …

In this issue of JAMA Internal Medicine, 3 important articles1-3 explore the use of
tocilizumab in coronavirus disease 2019 (COVID-19) pneumonia. Tocilizumab is a …

Methods| All patients in this study were admitted to the intensive care unit (ICU) of Radboud
University Medical Center. Plasma concentrations of the proinflammatory cytokines tumor …

Background: Normally, regulatory T cells (also known as T regulatory cells or Tregs) migrate
into inflamed tissues, dampening inflammatory responses and hastening tissue repair (1) …

Widespread availability of commercial assays that detect anti–severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) antibodies has enabled researchers to examine …

Background: A previous report of lung biopsies from a patient with coronavirus disease 2019
(COVID-19) and acute respiratory distress syndrome (ARDS) identified mononuclear cell …

Methods| The details of the trial have been previously reported (Supplement 1 and
Supplement 2). 3 Institutional review board approval was provided by Comités de Protection …

Importance Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …

Over the past year, the SARS-CoV-2 pandemic has swept the globe, resulting in an
enormous worldwide burden of infection and mortality. However, the additional toll resulting …

Cytokine storm–mediated organ injury continues to dominate current thinking as the primary
mechanism for coronavirus disease 2019 (COVID-19). Although there is an initial hyper …